CN103689590A - Health food for assisting reducing blood fat and preparation method thereof - Google Patents
Health food for assisting reducing blood fat and preparation method thereof Download PDFInfo
- Publication number
- CN103689590A CN103689590A CN201310631349.0A CN201310631349A CN103689590A CN 103689590 A CN103689590 A CN 103689590A CN 201310631349 A CN201310631349 A CN 201310631349A CN 103689590 A CN103689590 A CN 103689590A
- Authority
- CN
- China
- Prior art keywords
- extract
- health food
- agar
- preparation
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 28
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 210000004369 blood Anatomy 0.000 title abstract description 16
- 239000008280 blood Substances 0.000 title abstract description 16
- 230000001603 reducing effect Effects 0.000 title abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 24
- 229920001817 Agar Polymers 0.000 claims abstract description 16
- 235000010419 agar Nutrition 0.000 claims abstract description 16
- 244000037364 Cinnamomum aromaticum Species 0.000 claims abstract description 14
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims abstract description 14
- 241001092040 Crataegus Species 0.000 claims abstract description 7
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 claims abstract description 7
- 241000196324 Embryophyta Species 0.000 claims abstract description 4
- 239000008272 agar Substances 0.000 claims abstract description 4
- 240000006509 Gynostemma pentaphyllum Species 0.000 claims abstract 2
- 230000002402 anti-lipaemic effect Effects 0.000 claims description 19
- 241000206672 Gelidium Species 0.000 claims description 12
- 235000010443 alginic acid Nutrition 0.000 claims description 12
- 229920000615 alginic acid Polymers 0.000 claims description 12
- 241000748223 Alisma Species 0.000 claims description 9
- 239000000654 additive Substances 0.000 claims description 8
- 230000000996 additive effect Effects 0.000 claims description 8
- 235000020717 hawthorn extract Nutrition 0.000 claims description 7
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims description 6
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims description 6
- 235000009685 Crataegus X maligna Nutrition 0.000 claims description 6
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims description 6
- 235000009486 Crataegus bullatus Nutrition 0.000 claims description 6
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims description 6
- 235000009682 Crataegus limnophila Nutrition 0.000 claims description 6
- 235000004423 Crataegus monogyna Nutrition 0.000 claims description 6
- 235000002313 Crataegus paludosa Nutrition 0.000 claims description 6
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000206607 Porphyra umbilicalis Species 0.000 claims description 3
- 241000195474 Sargassum Species 0.000 claims description 3
- 241001261505 Undaria Species 0.000 claims description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 48
- 150000002632 lipids Chemical class 0.000 abstract description 19
- 235000012000 cholesterol Nutrition 0.000 abstract description 18
- 230000000694 effects Effects 0.000 abstract description 14
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 5
- 230000029142 excretion Effects 0.000 abstract description 4
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 235000014493 Crataegus Nutrition 0.000 abstract 1
- 230000000214 effect on organisms Effects 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 239000000661 sodium alginate Substances 0.000 abstract 1
- 235000010413 sodium alginate Nutrition 0.000 abstract 1
- 229940005550 sodium alginate Drugs 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 description 16
- 108010023302 HDL Cholesterol Proteins 0.000 description 12
- 108010028554 LDL Cholesterol Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 11
- 235000013305 food Nutrition 0.000 description 9
- 235000013325 dietary fiber Nutrition 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 201000005577 familial hyperlipidemia Diseases 0.000 description 6
- 241001065361 Gynostemma Species 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 4
- 241000786103 Steatomys pratensis Species 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 235000021590 normal diet Nutrition 0.000 description 4
- 229960002855 simvastatin Drugs 0.000 description 4
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical group C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241001474374 Blennius Species 0.000 description 2
- 208000032928 Dyslipidaemia Diseases 0.000 description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- RNXZPKOEJUFJON-UHFFFAOYSA-N aurantio-obtusin Chemical compound CC1=C(O)C(OC)=C2C(=O)C3=C(O)C(OC)=C(O)C=C3C(=O)C2=C1 RNXZPKOEJUFJON-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 2
- 239000005516 coenzyme A Substances 0.000 description 2
- 229940093530 coenzyme a Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003944 flavone Natural products 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 235000011949 flavones Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940089161 ginsenoside Drugs 0.000 description 2
- 229930182494 ginsenoside Natural products 0.000 description 2
- 229930187479 gypenoside Natural products 0.000 description 2
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- -1 trihydroxy trimethyl glutaryl Chemical group 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- NLOAQXKIIGTTRE-JSWHPQHOSA-N Alisol b acetate Chemical compound O([C@@H]1[C@@H](OC(C)=O)C[C@@H](C)C=2CC[C@]3(C)[C@@]4(C)CC[C@H]5C(C)(C)C(=O)CC[C@]5(C)[C@@H]4[C@@H](O)CC3=2)C1(C)C NLOAQXKIIGTTRE-JSWHPQHOSA-N 0.000 description 1
- NLOAQXKIIGTTRE-UHFFFAOYSA-N Alisol-B-Monoacetat Natural products C=12CC(O)C3C4(C)CCC(=O)C(C)(C)C4CCC3(C)C2(C)CCC=1C(C)CC(OC(C)=O)C1OC1(C)C NLOAQXKIIGTTRE-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229940122502 Cholesterol absorption inhibitor Drugs 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- 229940100228 acetyl coenzyme a Drugs 0.000 description 1
- AEMOLEFTQBMNLQ-BKBMJHBISA-N alpha-D-galacturonic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-BKBMJHBISA-N 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000010235 enterohepatic circulation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- PHPUXYRXPHEJDF-UHFFFAOYSA-N oxyphenisatine acetate Chemical group C1=CC(OC(=O)C)=CC=C1C1(C=2C=CC(OC(C)=O)=CC=2)C2=CC=CC=C2NC1=O PHPUXYRXPHEJDF-UHFFFAOYSA-N 0.000 description 1
- 229950000967 oxyphenisatine acetate Drugs 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- JAJWGJBVLPIOOH-IZYKLYLVSA-M sodium taurocholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 JAJWGJBVLPIOOH-IZYKLYLVSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Dispersion Chemistry (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to health food used for assisting reducing blood fat and a preparation method thereof. The health food mainly comprises the following material components: agar, sodium alginate, hawthorns, gynostemma pentaphyllum, rhizoma alismatis and semen cassia. By limiting components and proportion of the health food and a preparation method of each traditional Chinese medicine extract, absorption of cholesterol can be restrained, excretion of cholesterol and triglyceride is promoted, and absorption of lipid by small intestines is reduced, and therefore, effect of reducing blood fat is achieved from multiple aspects. Besides, all materials in the invention are natural plant materials, have advantages of being wide in material resource, low in cost and free from toxic and side effects on an organism, can effectively lower blood fat level of a patient with hyperlipaemia, and can suppress atherosclerosis.
Description
Technical field
The present invention relates to health food technology field, be specifically related to a kind ofly take agar-agar, algin as main, the health food that the Chinese medicine of take is auxiliary auxiliary antilipemic, the invention still further relates to the preparation method of this health food.
Background technology
The 2013(ESC2013 of ESC) on, reported the result of dyslipidemia international research (DYSIS) China research in mid-term, although show to have accepted fat-reducing medicament (LLD) treatment, but still having the patient of larger proportion, there is continuation dyslipidemia in the patient that especially cardiovascular risk is higher.Result of study prompting, still in the urgent need to optimizing lipid-lowering therapy scheme.
Fat metabolism or running make in blood plasma to be called when lipids contents is higher than normal range (NR) hyperlipemia extremely.High fat of blood is the most serious hazards of cardiovascular disease such as coronary heart disease, myocardial infarction." rubbish ", especially LDL-C and triglycerides that the blood fat increasing can be described as in blood vessel increase and can cause serious destruction to blood vessel, are " arch-criminals " who causes coronary heart disease, heart stalk.At present, lipid-regulation medicine clinically has: (1) trihydroxy trimethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitor (Statins); (2) fibrate (the special class of shellfish); (3) cholic acid chelating agent; (4) nicotinic acid class; (5) selective cholesterol absorption inhibitor (clothing Ezetimibe).Though the Western medicine of use is effective soon clinically, effect is obvious, long-term taking, drug toxicity is large, easily causes the symptoms such as stomach reaction, flush, headache, insomnia, weakness of limbs, and liver, kidney are had to certain damage.Traditional Chinese medicine for treating hyperlipidemia curative effect is slow, and the medication cycle is long.
Dietary fiber (dietary fiber is called for short DF) refers to not easily digested, the general name that the polysaccharide of take is main macromolecular substances, the condensate being comprised of materials such as cellulose, pectic substance, hemicellulose and glycoprotein.It is current a kind of functional food of generally acknowledging in the world, is called as the 7th nutrient except water, protein, carbohydrate, lipid, vitamin, the large nutrient of mineral matter six.Research shows, common atherosclerotic, hypertension, coronary heart disease, hyperlipemia are all relevant with dietary fiber intake deficiency.
The strong water absorbing capacity of dietary fiber can make the volume of ight soil in enteron aisle increase, and accelerates its transport speed, reduces the wherein time of harmful substance contact intestines wall; Lignin wherein can absorb bile acid, and pectin can reduce the absorption of intestines wall to cholesterol thereby reach in conjunction with cholesterol, and the effect of increased excretions of cholesterol metabolism, when body inner cholesterol content is declined, promotes bile acid to discharge from ight soil.
Agar-agar and algin all belong to soluble dietary fiber, have strong absorptive, can absorb the moisture in enteron aisle, and intestinal contents is expanded, and increase stool amount; Stimulating intestines wall, in the time of relief of constipation, be combined with cholesterol, promote cholesterol catabolism.Hawthorn, containing compositions such as vitamin Cs, flavones, has food digesting stomach fortifying, the loose stasis of blood of promoting the circulation of qi, changes the effect of turbid lipopenicillinase; Gynostemma pentaphylla, contains the compositions such as gypenoside, ginsenoside, has the effect of eliminating inflammation and expelling toxin, cough-relieving apophlegmatic; Rhizoma alismatis, contains the compositions such as Alisol B monoacetate, 24-acetylalisol A, has clearing damp and promoting diuresis, expels the heat-evil, changes the effect of turbid lipopenicillinase; Cassia seed, contains the compositions such as Chrysophanol, aurantio-obtusin, the effect that have removing heat to brighten vision, relaxes bowel.
Hawthorn, gynostemma pentaphylla, rhizoma alismatis, cassia seed, all have blood fat reducing function, and Yi Bei the world of medicine is extensively approved.But have no dietary fiber and Chinese Medicine and Clavicular, utilize it to act synergistically to reach the relevant report of reducing blood lipid object.Therefore, inventor is by dietary fiber compatibilities different from Chinese medicine, and the health food of exploitation auxiliary antilipemic has realistic meaning.
Summary of the invention
The object of the invention is to utilize the traditional medicine of China theoretical, a kind of health food that can auxiliary antilipemic is provided, this health food cost is low, source is wide, body is had no side effect, and has the effect that reduces hyperlipemic patients blood lipid level.
The present invention is achieved through the following technical solutions:
A health food for auxiliary antilipemic, its raw material comprises agar-agar 0～70wt%, algin 0～70wt%; Also comprise Chinese medicine additive, this Chinese medicine additive adopts the Alisma extract of 0～50wt%.
Described agar-agar derives from fragrant plant mentioned in ancient texts, agar, Yi Guzao or laver, and described algin derives from sea-tangle, undaria pinnitafida, bulk kelp, sheep dwell dish or sargassum.
Above-mentioned Chinese medicine additive adopts the Alisma extract of 0～50wt% and the Herb Gynostemmae Pentaphylli extract of 0～50wt%.
Above-mentioned Chinese medicine additive adopts the cassia seed extract of the haw thorn extract of 0～50wt%, the Herb Gynostemmae Pentaphylli extract of 0～50wt% and 0～50wt%.
A preparation method for the health food of auxiliary antilipemic, mixes each raw material according to weight proportion, grind to form smalls, incapsulates every 0.3-0.6 gram.
The preparation method of described haw thorn extract or Alisma extract or Herb Gynostemmae Pentaphylli extract or cassia seed extract is as follows: the ethanol water refluxing extraction that is 0～70% with concentration of volume percent by hawthorn or rhizoma alismatis or gynostemma pentaphylla or cassia seed 2～4 times, solid-to-liquid ratio 1:5～1:10, each 1～4h, filter and merge extract, reduced pressure concentration obtains concentrate,-80 ℃ of freeze overnight, freeze drying or spraying are dry.
The present invention compares with existing like product, has good lipid-lowering effect.Its feature is, by soluble dietary fiber and Chinese Medicine and Clavicular, can effectively bring into play the synergy of the two.The seaweed diet fiber such as agar-agar, algin has gel characteristic, forms gel in enteron aisle, and separation and detention cholesterol, affect cholesterol and contact with intestinal mucosa with digestive ferment, bile acid micelle, thereby is beneficial to the decomposition excretion of metabolism of lipid and cholesterol.Simultaneously, seaweed diet fiber can directly adsorb cholesterol (TC), triglycerides (TG) and the FBA (FBA) in enteron aisle and excrete with ight soil, the enteron aisle that has reduced TC, TG and FBA absorbs again, accelerated the catabolism of cholesterol, blocking-up enterohepatic circulation of bile acid, thus serum TC, TG level are reduced.Flavones in Chinese medicine hawthorn can, by suppressing the activity of trihydroxy trimethyl glutaryl coenzyme A (HMG-CoA) reductase, suppress the synthetic of endogenous cholesterol.Rhizoma alismatis can affect fatty decomposition, reduces the synthetic of acetyl coenzyme A, thereby affects the synthetic of cholesterol, and has the lipoids of prevention in blood, to be detained or to be penetrated into the ability of intestines inwall, promotes transportation and the removing of Blood Cholesterol.Gypenoside in gynostemma pentaphylla, ginsenoside etc. can increase metabolism and the excretion of cholesterol, thereby reduce Blood Cholesterol content.Archen in cassia seed can promote the metabolism of cholesterol.
Feature of the present invention is also, can reduce serum total cholesterol (TC), triglycerides (TG) and LDL-C (LDL-C) level simultaneously, and increasing high density lipoprotein cholesterol (HDL-C) level, reduces arteriosclerotic risk.
The specific embodiment
By the specific embodiment, further describe the present invention below, but the present invention is not limited only to following examples.Following examples only limit to curative effect of the present invention to be described further.
Embodiment mono-
A health food for auxiliary antilipemic, its each weight percentages of components is: agar-agar 50wt%, algin 30wt%, Alisma extract 20wt%.
Embodiment bis-
A health food for auxiliary antilipemic, its each weight percentages of components is: agar-agar 50wt%, algin 30wt%, Alisma extract 8wt%, Herb Gynostemmae Pentaphylli extract 12wt%.
Embodiment tri-
A health food for auxiliary antilipemic, its each weight percentages of components is: agar-agar 27wt%, algin 27wt%, haw thorn extract 18wt%, Herb Gynostemmae Pentaphylli extract 15wt%, cassia seed extract 13wt%.
Embodiment tetra-
A health food for auxiliary antilipemic, its each weight percentages of components is: agar-agar 55%, algin 10%, haw thorn extract 15%, Herb Gynostemmae Pentaphylli extract 10%, cassia seed extract 10%.
In the present invention, agar-agar derives from fragrant plant mentioned in ancient texts, agar, Yi Guzao or laver, and algin derives from sea-tangle, undaria pinnitafida, bulk kelp, sheep dwell dish or sargassum.
The preparation method of the health food of a kind of auxiliary antilipemic of the present invention, mixes each raw material according to weight proportion, grind to form smalls, incapsulates every 0.3-0.6 gram.
Wherein, the preparation method of described haw thorn extract or Alisma extract or Herb Gynostemmae Pentaphylli extract or cassia seed extract is as follows: the ethanol water refluxing extraction that is 0～70% with concentration of volume percent by hawthorn or rhizoma alismatis or gynostemma pentaphylla or cassia seed 2～4 times, solid-to-liquid ratio 1:5～1:10, each 1～4h, filter and merge extract, reduced pressure concentration obtains concentrate ,-80 ℃ of freeze overnight, freeze drying, is ground into powder.Or after merging extract, filtrate is condensed into the concentrate of relative density between 1.05～1.20, then uses pneumatic spray drying powdered, 150～200 ℃ of the inlet temperatures of spray dryer, 60～80 ℃ of outlet temperatures.
Pharmacodynamic observation
1. the reducing effect of the present invention to hyperlipemia lipid of mice level.
1.1 animal subject
Kunming kind SD mouse, male, 60, body weight 20 ± 2g, provides (credit number: SCXK (Fujian) 2005～0003) by Foochow Hai Wangfu medicine pharmaceutical Co. Ltd.
The foundation of 1.2 mouse hyperlipidemia models and administration
Mouse hyperlipidemia model adopts high lipid food to cause hyperlipemia method, and high lipid food formula is as follows: 78.8% normal diet; 10.0% lard; 10.0% yolk powder; 0.2% sodium taurocholate; 1.0% cholesterol.Blank group gives normal diet, and all the other each groups all give high lipid food.
Mouse adaptability was raised after one week, separated at random blank group of 12 conducts, gave normal diet, and all the other 48 give high lipid food, free diet drinking-water.After 10d, eye socket veniplex is got blood, measures serum total cholesterol (TC), total triglycerides (TG), HDL-C cholesterol (HDL-C), LDL-C (LDL-C) level.According to serum TC level, mouse is divided into model group, Simvastatin group, mono-group of embodiment, bis-groups of embodiment at random.
Mouse gavage every day 1 time, in gastric infusion, every day, free diet was drunk water, and dosage is 10mLkg
-1, successive administration 4 weeks.Each group gives respectively following tested medicine:
Mono-group of embodiment: gavage gives the compound of the health food in the embodiment of the present invention one;
Bis-groups of embodiment: gavage gives the compound of the health food in the embodiment of the present invention two;
Simvastatin group: gavage gives the Simvastatin of Isodose;
Blank group, model group: gavage gives Isodose physiological saline;
1.3 detect index
Detect T-CHOL (TC), triglycerides (TG), HDL-C (HDL-C) and LDL-C (LDL-C) level in serum.
1.4 experimental result
After 4 weeks, get blood, measure index of correlation, result is as table 1.
The impact of table 1 health food of the present invention on high fat lipid of mice
Note: with model group contrast, * P<0.05; With model group contrast, * * P<0.01.
Table 1 shows, the high fat mouse of reduction TC, TG, LDL-C level that embodiment mono-, embodiment bis-and Simvastatin group all can be in various degree, rising HDL-C level.With model group contrast, embodiment mono-and embodiment bis-all can utmost point conspicuousness reduce high fat mouse TC, TG, LDL-C level (P<0.01); The embodiment bis-high fat mouse HDL-C level (P<0.01) that can extremely significantly raise, the embodiment mono-high fat mouse HDL-C level (P<0.05) that can significantly raise.
As mentioned above, embodiment mono-and embodiment bis-all can effectively reduce high fat lipid of mice level, have the effect of auxiliary antilipemic.
2. the reducing effect of the present invention to hyperlipemia Serum Lipids in Experimental HypercholesterolemicRats.
2.1 animal subject
SPF level SD rat, male, 50, body weight 200 ± 20g, provides (credit number: SCXK (Fujian) 2005～0003) by Foochow Hai Wangfu medicine pharmaceutical Co. Ltd.
The foundation of 2.2 rat hyperlipidemia models and administration
Rat adopts high lipid food to cause hyperlipemia method, the high lipid food same mouse of filling a prescription.
Adaptability was raised after one week, separated at random blank group of 10 conducts, gave normal diet, and all the other give high lipid food, after 1～2 week, and the blood sampling of eyeground vein clump, separation of serum, detects indices in serum.And according to TC grouping, 10 every group, totally 4 groups, be respectively: dosage group and embodiment tri-low dose group in model group, embodiment tri-high dose group, embodiment tri-.Rat is pressed 10mLkg every day
-1gavage 1 time, gives high lipid food in the time of gavage, successive administration 4 weeks, and it is as follows that each organizes dosage:
The high, medium and low dosage group of table 2 embodiment tri-dosage (mLkg
-1)
Blank group and model group give the physiological saline of Isodose, and high, medium and low group of embodiment tri-is according to table 2 gastric infusion.
2.3 detect index
Detect T-CHOL (TC), triglycerides (TG), HDL-C (HDL-C) and LDL-C (LDL-C) level in serum.
2.4 experimental result
The impact of table 3 embodiment tri-on high fat rat fat
Note: with model group contrast, * P<0.05; With model group contrast, * * P<0.01.
Experimental result demonstration, embodiment tri-high doses, middle dosage group can extremely significantly reduce high fat Serum Lipids in Experimental HypercholesterolemicRats.
3. conclusion
Comprehensive Experiment result, gives the present invention 30 days of various dose continuously to high fat of blood animal, each dosage group and model group contrast, all can reduce serum total cholesterol, triglycerides and low-density lipoprotein cholesterol level, increasing high density lipoprotein cholesterol levels.
Criterion judgement according to the check of the < < of Ministry of Public Health health food with assessment technique standard (2003 editions) > >, the present invention has the effect of auxiliary antilipemic.
Claims (6)
1. a health food for auxiliary antilipemic, is characterized in that, its raw material comprises agar-agar 0～70wt%, algin 0～70wt%; Also comprise Chinese medicine additive, this Chinese medicine additive adopts the Alisma extract of 0～50wt%.
2. the health food of a kind of auxiliary antilipemic according to claim 1, is characterized in that, described agar-agar derives from fragrant plant mentioned in ancient texts, agar, Yi Guzao or laver, and described algin derives from sea-tangle, undaria pinnitafida, bulk kelp, sheep dwell dish or sargassum.
3. the health food of a kind of auxiliary antilipemic according to claim 1, is characterized in that, above-mentioned Chinese medicine additive adopts the Alisma extract of 0～50wt% and the Herb Gynostemmae Pentaphylli extract of 0～50wt%.
4. the health food of a kind of auxiliary antilipemic according to claim 1, is characterized in that, above-mentioned Chinese medicine additive adopts the cassia seed extract of the haw thorn extract of 0～50wt%, the Herb Gynostemmae Pentaphylli extract of 0～50wt% and 0～50wt%.
5. according to the preparation method of the health food of a kind of auxiliary antilipemic described in claim 1-4 any one, it is characterized in that: each raw material is mixed according to weight proportion, grind to form smalls, incapsulate, every 0.3-0.6 gram.
6. the preparation method of the health food of a kind of auxiliary antilipemic according to claim 5, it is characterized in that: the preparation method of described haw thorn extract or Alisma extract or Herb Gynostemmae Pentaphylli extract or cassia seed extract is as follows: the ethanol water refluxing extraction that is 0～70% with concentration of volume percent by hawthorn or rhizoma alismatis or gynostemma pentaphylla or cassia seed 2～4 times, solid-to-liquid ratio 1:5～1:10, each 1～4h, filter and merge extract, reduced pressure concentration obtains concentrate,-80 ℃ of freeze overnight, freeze drying or spraying are dry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310631349.0A CN103689590B (en) | 2013-11-29 | 2013-11-29 | Health food of a kind of auxiliary antilipemic and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310631349.0A CN103689590B (en) | 2013-11-29 | 2013-11-29 | Health food of a kind of auxiliary antilipemic and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103689590A true CN103689590A (en) | 2014-04-02 |
| CN103689590B CN103689590B (en) | 2016-04-13 |
Family
ID=50351378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310631349.0A Active CN103689590B (en) | 2013-11-29 | 2013-11-29 | Health food of a kind of auxiliary antilipemic and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103689590B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104757464A (en) * | 2015-04-30 | 2015-07-08 | 黄馨莹 | Haw flake tablet making method |
| CN108272087A (en) * | 2018-01-30 | 2018-07-13 | 山东汇润膳食堂股份有限公司 | A kind of blood fat reducing food and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087495A (en) * | 1993-11-16 | 1994-06-08 | 朱建华 | Low-calorie health-care beverage and preparation method thereof |
| CN1336193A (en) * | 2000-07-31 | 2002-02-20 | 雷学军 | Antilipenic functional water containing natural medicine component and its compounding process |
| CN101095520A (en) * | 2006-06-26 | 2008-01-02 | 江苏晶隆海洋产业发展有限公司 | Functional food with lipid-lowering and weight-losing effects |
| CN101613378A (en) * | 2009-07-17 | 2009-12-30 | 辽宁大学 | Acidic oligosaccharide and application thereof with fat-reducing and lipid-lowering effect |
| CN101890094A (en) * | 2010-04-16 | 2010-11-24 | 新疆英惠堂生物科技有限公司 | Health care product for assisting in reducing blood fat and preparation method thereof |
| CN102246920A (en) * | 2011-08-18 | 2011-11-23 | 高益槐 | Health-care food capable of assisting in reduction of blood fat and preparation method thereof |
| CN102784254A (en) * | 2012-03-20 | 2012-11-21 | 河南九势制药股份有限公司 | Chinese medicine composition assisting in reducing blood fat and preparation method of Chinese medicine composition |
-
2013
- 2013-11-29 CN CN201310631349.0A patent/CN103689590B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1087495A (en) * | 1993-11-16 | 1994-06-08 | 朱建华 | Low-calorie health-care beverage and preparation method thereof |
| CN1336193A (en) * | 2000-07-31 | 2002-02-20 | 雷学军 | Antilipenic functional water containing natural medicine component and its compounding process |
| CN101095520A (en) * | 2006-06-26 | 2008-01-02 | 江苏晶隆海洋产业发展有限公司 | Functional food with lipid-lowering and weight-losing effects |
| CN101613378A (en) * | 2009-07-17 | 2009-12-30 | 辽宁大学 | Acidic oligosaccharide and application thereof with fat-reducing and lipid-lowering effect |
| CN101890094A (en) * | 2010-04-16 | 2010-11-24 | 新疆英惠堂生物科技有限公司 | Health care product for assisting in reducing blood fat and preparation method thereof |
| CN102246920A (en) * | 2011-08-18 | 2011-11-23 | 高益槐 | Health-care food capable of assisting in reduction of blood fat and preparation method thereof |
| CN102784254A (en) * | 2012-03-20 | 2012-11-21 | 河南九势制药股份有限公司 | Chinese medicine composition assisting in reducing blood fat and preparation method of Chinese medicine composition |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104757464A (en) * | 2015-04-30 | 2015-07-08 | 黄馨莹 | Haw flake tablet making method |
| CN108272087A (en) * | 2018-01-30 | 2018-07-13 | 山东汇润膳食堂股份有限公司 | A kind of blood fat reducing food and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103689590B (en) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101606704B (en) | Dietary fiber food with various functional actions | |
| Luan et al. | Polysaccharides from Laminaria japonica: An insight into the current research on structural features and biological properties | |
| CN101560267B (en) | Preparation method of polysaccharide selenite | |
| CN102008516B (en) | Ultrafine powder traditional Chinese medicine for treating tumors | |
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| CN105727205A (en) | Composition with weight losing and blood fat reducing functions and preparing method and application thereof | |
| CN103211866A (en) | Soft capsule used for improving body immunity and heart and cerebral vessel function | |
| CN103689590B (en) | Health food of a kind of auxiliary antilipemic and preparation method thereof | |
| CN102151284B (en) | Composition containing fucoidin sulfate and application thereof | |
| CN102784247B (en) | Chitosan oligosaccharide containing medicine composition with blood fat reducing function | |
| CN102640825B (en) | Lipid-lowering tea for regulating blood lipid | |
| CN101613378A (en) | Acidic oligosaccharide and application thereof with fat-reducing and lipid-lowering effect | |
| CN102716414A (en) | Anti-tumor medicinal composition containing algal polysaccharide sulfate and preparation method for composition | |
| KR101446277B1 (en) | A funcitional food increased immunity for natural drugs and method of funcitional food | |
| Jung et al. | L-ascorbic acid addition to chitosan reduces body weight in overweight women | |
| CN104288566B (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
| CN107594274A (en) | A kind of compound edible mushroom drink of pre- anti-cancer and preparation method thereof | |
| JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
| CN102846720B (en) | Composite for lowering blood fat and improving anoxia endurance | |
| Andrade et al. | Beta-Glucans as a therapeutic agent: Literature Review | |
| CN103503943B (en) | Lipid-lowering biscuit and preparation method thereof | |
| KR101201286B1 (en) | Functional composition having the lipolysis effect and food having the same | |
| CN102379904B (en) | Proteoglycan protein tablet and preparation method thereof | |
| CN107375847A (en) | A kind of slimming medicine, its preparation method and application | |
| CN106798748A (en) | Herba Lycopi's polyoses producing method and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |